Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been given a consensus recommendation of “Moderate Buy” by the twenty-two brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, twenty have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $119.50.

Several research analysts recently commented on KYMR shares. Stephens lifted their target price on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Monday. Mizuho lifted their price objective on Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. B. Riley Financial boosted their price objective on Kymera Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Stifel Nicolaus set a $114.00 target price on Kymera Therapeutics in a report on Monday, December 8th. Finally, Bank of America upped their target price on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th.

Kymera Therapeutics Trading Down 4.2%

Shares of NASDAQ:KYMR opened at $86.35 on Friday. The stock has a market capitalization of $7.05 billion, a PE ratio of -23.46 and a beta of 2.20. Kymera Therapeutics has a 1 year low of $19.44 and a 1 year high of $103.00. The firm has a fifty day moving average price of $78.69 and a 200 day moving average price of $66.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The company had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.Kymera Therapeutics’s quarterly revenue was down 60.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.88) EPS. On average, sell-side analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In related news, Director Bros. Advisors Lp Baker bought 2,005,813 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was acquired at an average cost of $86.00 per share, with a total value of $172,499,918.00. Following the acquisition, the director owned 7,955,916 shares in the company, valued at approximately $684,208,776. This represents a 33.71% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $89.76, for a total value of $448,800.00. The disclosure for this sale is available in the SEC filing. Insiders sold 450,895 shares of company stock valued at $40,486,151 over the last 90 days. Corporate insiders own 16.01% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently bought and sold shares of the business. Baker BROS. Advisors LP raised its stake in shares of Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after acquiring an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after buying an additional 1,124,747 shares during the period. Vanguard Group Inc. boosted its stake in Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after acquiring an additional 1,061,957 shares during the period. Finally, BVF Inc. IL raised its position in shares of Kymera Therapeutics by 6.6% during the 2nd quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock valued at $240,138,000 after acquiring an additional 340,909 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.